OTCQX:MRVFF - Post by User
Post by
TheRock07on Jul 16, 2016 8:06am
319 Views
Post# 25058426
July 11 Presentation
July 11 Presentation Q2 numbers are posted.
Just over 10,000 per week for Q2 or about 135,000 btles for the quarter.
Prorata to Q1, indicates about $9.5 million in total sales or about $38 million run rate .
About $17.5 million for first half.
Second half is about 35% stronger so $23 million or more in the second half seems reasonable.
This puts us on track for adjusted Ebitda of about $18.5 million or about $1.50 per share.
No debt and a rapidly building cash position of perhaps $2 per share or more by exit 2016, Nuvo should exit 2016 at or above $15.
Out licensing or accretive acquisition of other drugs would boost that valuation.
Otherwise, a somnambulant steady increase to $15 per share as the next 3 quarters report.
I can take that..